You can buy or sell Forty Seven and other stocks, options, ETFs, and crypto commission-free!
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. Read More The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Expected Nov 13, After Hours